Literature DB >> 8304304

Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. The Misoprostol Study Group.

J G Kim1, D Y Graham.   

Abstract

OBJECTIVES: Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use are both common causes of peptic ulcer. It remains unclear whether H. pylori/NSAID interactions occur, and if they do, with what result(s).
METHODS: We prospectively evaluated development of gastric or duodenal ulcers in 181 arthritics followed for up to 3 months while receiving an NSAID chronically and with no active anti-ulcer medications. H. pylori status was determined with a sensitive, specific ELISA for anti-H. pylori IgG.
RESULTS: H. pylori infection was present in 51%; peptic ulcers developed in 24. H. pylori infection was present in only 36% of those who developed a duodenal ulcer. Stepwise logistic regression analysis indicated none of the variable factors of age, gender, alcohol consumption, type of arthritis, or H. pylori status were significantly associated with development of peptic ulceration.
CONCLUSIONS: These data suggest that H. pylori does not confer increased risk of ulceration in arthritics receiving NSAIDs chronically.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8304304

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  12 in total

1.  Effects of nonsteroidal anti-inflammatory drugs on Helicobacter pylori-infected gastric mucosae of mice: apoptosis, cell proliferation, and inflammatory activity.

Authors:  T I Kim; Y C Lee; K H Lee; J H Han; C Y Chon; Y M Moon; J K Kang; I S Park
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 2.  [Risk of ulcer and its prophylaxis in therapy with non-steroidal antirheumatic drugs].

Authors:  L Köhler; W Mau; H Zeidler
Journal:  Med Klin (Munich)       Date:  1997-12-15

3.  Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.

Authors:  G Bianchi Porro; F Parente; V Imbesi; F Montrone; I Caruso
Journal:  Gut       Date:  1996-07       Impact factor: 23.059

Review 4.  NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management.

Authors:  Francis K L Chan
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 5.  An evidence-based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus. Canadian NSAID Consensus Participants.

Authors:  H Tannenbaum; P Davis; A S Russell; M H Atkinson; W Maksymowych; S H Huang; M Bell; G A Hawker; A Juby; S Vanner; J Sibley
Journal:  CMAJ       Date:  1996-07-01       Impact factor: 8.262

6.  Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the elderly: a case-control study.

Authors:  A Pilotto; G Leandro; F Di Mario; M Franceschi; L Bozzola; G Valerio
Journal:  Dig Dis Sci       Date:  1997-03       Impact factor: 3.199

Review 7.  From peptic ulcer disease to NSAID gastropathy. An evolving nosology.

Authors:  S H Roth
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

8.  Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens.

Authors:  L Santucci; S Fiorucci; L Patoia; F M Di Matteo; P M Brunori; A Morelli
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

Review 9.  Pain treatment in multimorbid patients, the older population and other high-risk groups. The clinical challenge of reducing toxicity.

Authors:  C H Wilder-Smith
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

Review 10.  Helicobacter pylori and non-steroidal anti-inflammatory drugs: does infection affect the outcome of NSAID therapy?

Authors:  D M McCarthy
Journal:  Yale J Biol Med       Date:  1998 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.